To view this email as a web page, click here

Today's Rundown

Featured Story

Regeneron scraps sustained-release Eylea alliance with Ocular

Regeneron has ended a collaboration with Ocular Therapeutix to develop a sustained-release version of Eylea. The termination follows the failure of the first formulation to meet the goals of the program and the submission of other candidates to Regeneron for preclinical assessment.

read more

Top Stories

Oyster Point sells China rights to nasal sprays for eye disease

Oyster Point Pharma has sold the rights to two nasal sprays for patients with dry eye disease in greater China to Ji Xing Pharmaceuticals for $17.5 million upfront. The deal comes ahead of an FDA decision that could make one of the drugs the first nasal spray approved for dry eye disease. 

read more

Eyevensys bags $12M to test non-viral gene therapy delivery tech

Eyevensys has raised $12 million to fund development of gene therapies based on its ocular delivery platform. The biotech is using an electrical pulse generator and an ocular device to get plasmids to targets in the eye without using the viral vectors typically needed to administer gene therapies.

read more

Inflammasome gets Gates grant for dual HIV-birth control implant

Inflammasome Therapeutics has received funding to develop a sustained-release formulation that provides protection from HIV infection and birth control for 12 months. The Bill & Melinda Gates Foundation is bankrolling the project through a $1.3 million grant. 

read more

Philip Morris' biopharma addiction ramps up, as heart attack biotech OtiTopic joins cigarette maker on 'Beyond Nicotine' journey

Philip Morris first starting selling tobacco products to the public all the way back in 1847, but, more than 170 years later, the company has read the tea leaves and the future is “smoke-free.”

read more

Novartis back with bid for 'multibillion-dollar' Zolgensma expansion in older SMA patients as FDA lifts clinical hold

As Novartis' gene therapy Zolgensma makes inroads in newborns diagnosed with spinal muscular atrophy, the company is looking to expand the drug’s reach to older patients with a new formulation. After a safety scare and a regulatory setback, the Swiss pharma is now back on track with that plan.

read more

Resources

eBook: Accelerate recruitment with a decentralized clinical trial strategy

Learn how a decentralized clinical trial strategy improves patient recruitment, reduces drop-out rates, and ultimately streamlines the path to the next trial phase.

Whitepaper: How to build a robust packaging strategy for rapid commercialization

Learn how to build a robust packaging strategy and the key technical considerations in packaging design and operational planning to enable rapid commercialization of pharmaceuticals.

Whitepaper: Understanding the CMC regulatory landscape for cell and gene therapy products

Learn how regulations are changing and key considerations for commercializing cell and gene therapies without sacrificing quality.

Whitepaper: Navigating the Digital Transformation Journey

Uncover the real impact of “digital transformation” with practical advice to help you plan your own transformative journey to a harmonized digital ecosystem.

eBook: Get solutions to market faster

Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization.

Content Hub: Process Intensification Resource Center

A one-stop hub for Cytiva resources to support process intesification

Content Hub: Emerging Biotech Resource Center

A one-stop hub for Cytiva resources to support process development and manufacturing of your novel molecule

Content Hub: Remarque Systems Resource Hub

Remarque Systems consolidates data, then layers on visualization and automated metrics to generate consistent, actionable data insights in real-time. Click here for more info. 

Content Hub: How to improve the virtual work you do every day

We enable virtual work — offering over-time sessions where participants are more focused, insights are more diverse and business goals are met.

Webinar: Patient-Focused Drug Design: Through the Lens of Real-World Case Studies, Clinical Evidence and Advanced Delivery Solutions

Discover the current state of patient-focused dose design through clinical evidence, real-world case studies and patient preference-driven drug design solutions that can help develop better treatments and successful real-world outcomes.

eBook: Drug Design and the Patient Journey

This eBook features insights from experts in the industry on patient-centric drug development challenges and strategies on advancing drug design and development effectively.

eBrief: Drug Product Process Development: Ensuring a Consistent, High-quality Biologic

Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase.

Events